Skip to main content
. 2022 Dec 2;71(48):1531–1537. doi: 10.15585/mmwr.mm7148e2

FIGURE.

The figure is a flow chart outlining the identification of patient records in the Cosmos data set that were used to examine the association between receiving a Paxlovid (nirmatrelvir-ritonavir) prescription within 5 days of COVID-19 diagnosis and COVID-19–associated hospitalization within 30 days in the United States during April–September 2022.

Identification of patients with COVID-19* who were eligible for treatment with Paxlovid (nirmatrelvir-ritonavir) — Cosmos,† United States, April–September 2022

Abbreviation: NAAT = nucleic acid amplification test.

* Patients were classified as having COVID-19 based on a diagnosis code for COVID-19 or based on a positive SARS-CoV-2 antigen or nucleic acid amplification test. Among 1,713,120 adults aged ≥18 years who met this definition during April 1–August 1, 2022, 930,847 had a diagnosis code only, 159,878 had a positive NAAT result only, 12,874 had a positive antigen test result only, and 609,521 had both a diagnosis code and positive test result (NAAT or antigen test). Exclusions summarized at each level of the flow chart are not mutually exclusive.

† Cosmos is an electronic health record dataset that includes information from >160 million persons in U.S. health systems covered by Epic. https://cosmos.epic.com

HHS Vulnerability Disclosure